Literature DB >> 2910902

Identification of a single nucleotide change in the hypoxanthine-guanine phosphoribosyltransferase gene (HPRTYale) responsible for Lesch-Nyhan syndrome.

S Fujimori1, B L Davidson, W N Kelley, T D Palella.   

Abstract

Complete deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) causes the Lesch-Nyhan syndrome. Previous characterization of a mutant form of HPRT, HPRTYale, from a subject with the Lesch-Nyhan syndrome revealed normal mRNA and protein concentrations, no residual catalytic activity, and cathodal migration upon PAGE. We have cloned and sequenced HPRTYale cDNA. The nucleotide sequence of full-length HPRTYale cDNA revealed a single nucleotide substitution compared with normal HPRT cDNA: G----C at nucleotide position 211. This transversion predicts substitution of arginine for glycine at amino acid position 71, explaining the cathodal migration of HPRTYale. Chou-Fasman secondary structure analysis predicts a change in the probability of beta-turn formation in the region containing the mutation. Inclusion of the bulky arginine side chain in place of glycine probably disrupts protein folding as well. Cloning mutant forms of cDNA allows identification of specific mutations, provides insight into mutational mechanisms, and facilitates structure-function analysis of mutant proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910902      PMCID: PMC303636          DOI: 10.1172/JCI113846

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

Review 1.  Disease diagnosis by recombinant DNA methods.

Authors:  C T Caskey
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

2.  Screening lambdagt recombinant clones by hybridization to single plaques in situ.

Authors:  W D Benton; R W Davis
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

3.  Mutations affecting the 12th and 61st amino acids of p21 protein result in decreased probability of beta-turn occurrence around the mutation positions: a prediction.

Authors:  M Murakami
Journal:  J Theor Biol       Date:  1985-05-21       Impact factor: 2.691

Review 4.  Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes.

Authors:  J M Wilson; A B Young; W N Kelley
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

5.  Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination.

Authors:  M D Biggin; T J Gibson; G F Hong
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  Molecular evidence for new mutation at the hprt locus in Lesch-Nyhan patients.

Authors:  T P Yang; P I Patel; A C Chinault; J T Stout; L G Jackson; B M Hildebrand; C T Caskey
Journal:  Nature       Date:  1984 Aug 2-8       Impact factor: 49.962

7.  A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man.

Authors:  J M Wilson; J T Stout; T D Palella; B L Davidson; W N Kelley; C T Caskey
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

8.  Identification and localization of mutations at the Lesch-Nyhan locus by ribonuclease A cleavage.

Authors:  R A Gibbs; C T Caskey
Journal:  Science       Date:  1987-04-17       Impact factor: 47.728

9.  Expression of human and Chinese hamster hypoxanthine-guanine phosphoribosyltransferase cDNA recombinants in cultured Lesch-Nyhan and Chinese hamster fibroblasts.

Authors:  J Brennand; D S Konecki; C T Caskey
Journal:  J Biol Chem       Date:  1983-08-25       Impact factor: 5.157

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  8 in total

1.  Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in ten subjects determined by direct sequencing of amplified transcripts.

Authors:  B L Davidson; S A Tarlé; T D Palella; W N Kelley
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

2.  Stable gene expression from a mammalian artificial chromosome.

Authors:  B R Grimes; D Schindelhauer; N I McGill; A Ross; T A Ebersole; H J Cooke
Journal:  EMBO Rep       Date:  2001-09-24       Impact factor: 8.807

Review 3.  Atrial fibrillation.

Authors:  Bianca J J M Brundel; Xun Ai; Mellanie True Hills; Myrthe F Kuipers; Gregory Y H Lip; Natasja M S de Groot
Journal:  Nat Rev Dis Primers       Date:  2022-04-07       Impact factor: 52.329

4.  Molecular analyses of a Lesch-Nyhan syndrome mutation (hprtMontreal) by use of T-lymphocyte cultures.

Authors:  T R Skopek; L Recio; D Simpson; L Dallaire; S B Melancon; H Ogier; J P O'Neill; M T Falta; J A Nicklas; R J Albertini
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

5.  Identification of two new nucleotide mutations (HPRTUtrecht and HPRTMadrid) in exon 3 of the human hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene.

Authors:  A G Bouwens-Rombouts; M J van den Boogaard; J G Puig; F A Mateos; R C Hennekam; M G Tilanus
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

6.  Hypoxanthine guanine phosphoribosyltransferase deficiency: nucleotide substitution causing Lesch-Nyhan syndrome identified for the first time among Japanese.

Authors:  S Fujimori; N Kamatani; Y Nishida; N Ogasawara; I Akaoka
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

Review 7.  A review of the molecular basis of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency.

Authors:  D G Sculley; P A Dawson; B T Emmerson; R B Gordon
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

8.  Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: identification of point mutations in Japanese patients with Lesch-Nyhan syndrome and hereditary gout and their permanent expression in an HPRT-deficient mouse cell line.

Authors:  J Tohyama; E Nanba; K Ohno
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.